Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
Clin Hematol Int
.
2023 Aug 28;5(4):1-4.
doi: 10.46989/001c.87501.
eCollection 2023.
Authors
Ahmed H Al Sharie
1
,
Balqis M Abu Mousa
1
,
Ahmad O Alomari
1
Affiliation
1
Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
PMID:
37752987
PMCID:
PMC10515879
DOI:
10.46989/001c.87501
No abstract available
Keywords:
Hodgkin lymphoma; Refractory; Relapsed; Ruxolitinib.
Publication types
Review